Efficacy of asfotase alfa in a patient with adult-onset hypophosphatasia without obvious bone lesions: a case report with review of literature

被引:0
作者
Nishikage, Seiji [1 ]
Yamamoto, Masaaki [1 ]
Niikura, Takahiro [2 ]
Inaba, Yuiko [3 ]
Akiyama, Tomoyuki [4 ]
Harada, Risa [5 ]
Sakai, Yoshitada [5 ]
Sugawara, Kenji [1 ]
Tachikawa, Kanako [6 ]
Michigami, Toshimi [6 ]
Ogawa, Wataru [1 ]
Fukuoka, Hidenori [3 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Diabet & Endocrinol, Kobe 6500017, Japan
[2] Kobe Univ, Grad Sch Med, Dept Orthoped Surg, Kobe 6500017, Japan
[3] Kobe Univ Hosp, Div Diabet & Endocrinol, 7-5-2Kusunoki Cho,Chuo Ku, Kobe, Hyogo 6500017, Japan
[4] Okayama Univ, Okayama Univ Hosp, Grad Sch Med Dent & Pharmaceut Sci, Dept Child Neurol, Okayama 7008558, Japan
[5] Kobe Univ, Grad Sch Med, Div Rehabil Med, Kobe 6500017, Japan
[6] Osaka Prefectural Hosp Org, Osaka Womens & Childrens Hosp, Dept Bone & Mineral Res, Osaka 5941101, Japan
关键词
Hypophosphatasia; Adult-onset hypophosphatasia; Asfotase alfa; Enzyme replacement therapy; Quality of life; ALKALINE-PHOSPHATASE;
D O I
10.1507/endocrj.EJ24-0431
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The use of asfotase alfa, a bone-targeted recombinant alkaline phosphatase (ALP) enzyme, for the treatment of adult-onset hypophosphatasia (HPP) remains controversial, particularly in patients without evident bone abnormalities. We report the case of a 41-year-old woman with a history of Graves' disease, who presented with progressive joint pain and severe fatigue. Despite the absence of bone lesions, the patient was diagnosed with HPP based on persistently low alkaline phosphatase levels, family history, and a novel heterozygous ALPL variant (p.Ala205Thr). Functional analysis revealed a dominant-negative effect for this variant. Her symptoms significantly interfered with her daily activities owing to uncontrolled pain and loss of motor function and were so exacerbated that high doses of acetaminophen and NSAIDs were ineffective. Treatment with asfotase alfa was initiated based on multidisciplinary team consensus. Within 3 months of treatment initiation, her pain improved significantly, as indicated by reduced scores on the visual analog scale from 6.6 to 0.9, and elimination of the need for analgesics. Additionally, her grip strength increased, and her urinary phosphoethanolamine levels and serum pyridoxal 5'-phosphate/pyridoxal ratio decreased from 90.4 to 57.8 mu mol/g<middle dot>creatinine and from 4.6 to 0.4, respectively. These improvements have been maintained for more than 2 years. This case highlights the potential of asfotase alfa in effectively alleviating symptoms in patients with adult-onset HPP without bone lesions, emphasizing the importance of patient selection and outcome monitoring. We also discuss the key considerations for future treatment, supported by a literature review of asfotase alfa in adult patients with HPP.
引用
收藏
页码:437 / 445
页数:9
相关论文
共 35 条
[1]   Pyridoxal 5′-phosphate and related metabolites in hypophosphatasia: Effects of enzyme replacement therapy [J].
Akiyama, Tomoyuki ;
Kubota, Takuo ;
Ozono, Keiichi ;
Michigami, Toshimi ;
Kobayashi, Daisuke ;
Takeyari, Shinji ;
Sugiyama, Yuichiro ;
Noda, Masahiro ;
Harada, Daisuke ;
Namba, Noriyuki ;
Suzuki, Atsushi ;
Utoyama, Maiko ;
Kitanaka, Sachiko ;
Uematsu, Mitsugu ;
Mitani, Yusuke ;
Matsunami, Kunihiro ;
Takishima, Shigeru ;
Ogawa, Erika ;
Kobayashi, Katsuhiro .
MOLECULAR GENETICS AND METABOLISM, 2018, 125 (1-2) :174-180
[2]   Hypophosphatasia: presentation and response to asfotase alfa [J].
Alsarraf, F. ;
Ali, D. S. ;
Almonaei, K. ;
Al-Alwani, H. ;
Khan, A. A. ;
Brandi, M. L. .
OSTEOPOROSIS INTERNATIONAL, 2024, 35 (04) :717-725
[3]   Clinical spectrum of hypophosphatasia diagnosed in adults [J].
Berkseth, Kathryn E. ;
Tebben, Peter J. ;
Drake, Matthew T. ;
Hefferan, Theresa E. ;
Jewison, Donna E. ;
Wermers, Robert A. .
BONE, 2013, 54 (01) :21-27
[4]   Analysis of localization of mutated tissue nonspecific alkaline phosphatase proteins associated with neonatal hypophosphatasia using green fluorescent protein chimeras [J].
Cai, GM ;
Michigami, T ;
Yamamoto, T ;
Yasui, N ;
Satomura, K ;
Yamagata, M ;
Shima, M ;
Nakajima, S ;
Mushiake, S ;
Okada, S ;
Ozono, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) :3936-3942
[5]   HYPOPHOSPHATASIA - DENTAL ASPECTS AND MODE OF INHERITANCE [J].
CHAPPLE, ILC .
JOURNAL OF CLINICAL PERIODONTOLOGY, 1993, 20 (09) :615-622
[6]   Adult hypophosphatasia manifests in a marathon runner [J].
Fanous, Nada ;
Barb, Diana .
BMJ CASE REPORTS, 2020, 13 (09)
[7]   Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan [J].
Fukuhara, S ;
Bito, S ;
Green, J ;
Hsiao, A ;
Kurokawa, K .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1037-1044
[8]   Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey [J].
Fukuhara, S ;
Ware, JE ;
Kosinski, M ;
Wada, S ;
Gandek, B .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1045-1053
[9]  
Fukuhara S, 2015, Manual of SF-36v2 Japanese version
[10]   Mild hypophosphatasia may be twice as prevalent as previously estimated: an effective clinical algorithm to detect undiagnosed cases [J].
Gonzalez-Cejudo, Trinidad ;
Villa-Suarez, Juan Miguel ;
Ferrer-Millan, Maria ;
Andujar-Vera, Francisco ;
Contreras-Bolivar, Victoria ;
Andreo-Lopez, Maria Carmen ;
Gomez-Vida, Jose Maria ;
Martinez-Heredia, Luis ;
Gonzalez-Salvatierra, Sheila ;
Munoz, Tomas de Haro ;
Garcia-Fontana, Cristina ;
Munoz-Torres, Manuel ;
Garcia-Fontana, Beatriz .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2024, 62 (01) :128-137